Moderna Reports the P-III Study Data of mRNA-1283 Vaccine to Prevent COVID-19
Shots:
- The P-III (NextCOVE) trial investigates the safety & efficacy of mRNA-1283 (50% received 10μg) vs Spikevax (50% received 50μg) among ≥12yrs. old participants (n=11,400) to prevent COVID-19
- The study reached its 1EPs, showing the superiority of the vaccine with greater effectiveness achieved among adults aged ≥18yrs. and a trend in adults aged ≥65yrs. Data will be highlighted at future conferences along with submission for publication
- The data aligned with the immunogenicity outcomes revealed in Mar 2024, depicting the formation of neutralizing antibodies against Omicron BA.4/5 and original SARS-CoV-2 among adults aged ≥65yrs.
Ref: Moderna | Image: Moderna
Related News:- Moderna Reports the P-III Study Data of mRNA-1083 Vaccine Against Influenza and COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
